Cabel, 

Great question. However, the answer all depends on what they find in BETonMACE. It's not just looking at MACE, but also several secondary outcomes including kidney function (i.e. eGFR, alkaline phosphatase), cognitive function, HDL/apo-A1, non-HDL lipids (i.e. LDL, apoB, TG), glucose homeodynamics (fasting glucose, fasting insulin, HbA1c), inflammatory markers (hsCRP), coagulation markers (fibrinogen) and probably some other stuff I forgot off the top of my head. The more of the above list that BETonMACE/apabetalone finds to be improved AND statistically significant, the more indications/risk factors that apabetalone may be able to be marketed for. Some of the secondary outcomes listed above may just serve as fuel for follow up trials but others may be able to be used in the initial NDA/MMA applications and be marketed to compete with some of the current market just off this BETonMACE data.

BearDownAZ